Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman has reiterated a Buy rating on Emergent BioSolutions (NYSE:EBS) and maintained a price target of $8.
June 24, 2024 | 3:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman has reiterated a Buy rating on Emergent BioSolutions (NYSE:EBS) and maintained a price target of $8.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100